Nuclear Medicine Market 2019 Precise Outlook- Curium Pharma, Nordion, Inc. etc.

Nuclear Medicine Market Snapshot:

Nuclear medicine is a multidisciplinary field that specializes in radioactive material used for diagnosing and treating various diseases in neurology, endocrine system, cardiology, gastrointestinal system, and cancers. Radiopharmaceuticals comprise of a radioactive tracer that is injected in the patient's body. Later, the gamma-rays are released in the body to display images using the Single-photon Emission Computed Tomography (SPECT) and Positron emission tomography (PET) imaging modalities. Nuclear medicine offer umpteen benefits, including early detection, accurate diagnosis, and detail examination of different diseases compared to conventional imaging methods.

The ongoing advancement in the field of radiopharmaceutical is providing practical insights for studying micro-level physiological activities in cancer proliferation, myocardial perfusion in cardiac arrest, ventilation in lungs in severe pneumonia, thyroid, and parathyroid stimulation in case of hyperthyroidism, and metabolic imaging in case of liver disorders, among others. Thereby, nuclear medicines are extensively used in the R&D activities for developing next-generation therapeutics using radiopharmaceuticals conjugates with antibodies, biologic drugs and peptides, targeted drug deliveries, and dose optimization, among others.

Globally, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, respiratory disorders, neurological disorders, and metabolic disorders, are increasing at a concerning rate.  As per the Lymphoma Research Foundation, in the U.S., over 1, 00,000 people are diagnosed with lymphoma every year, and it is the most common cancers among children and adults. According to the Global burden of diseases, cardiovascular diseases is one of the leading cause of death, and about 18 million people died of CVD in 2018, and about 35 million people are suffering from heart-related ailments, which is further boosting the demand for nuclear medicines for both diagnostic and therapeutic purposes.

Nuclear medicines have a shorter biological life (less than one day), which is further impeding the market growth to a certain extent. For the record, the biological half-life of nuclear medicines is the time taken to decrease the pharmaceutical's concentration by 50 % of its full concentration in a given tissue, organ, or body. For instance, Technetium 99m is used in Single-photon Emission Computed Tomography (SPECT) preparations and has to be used within less than 12 hours. Similarly, Fluorine-18 used in Positron Emission Tomography (PET), has to be used in 109 minutes. Lastly, Indium-111 nuclear medicine used for white blood cell scans, to search for hidden infections, has a half-life of just 99 minutes.

The global nuclear medicines market is consolidated with the presence of leading players that are arduously working to increase the product launches and are heavily investing in the R&D activities to attend to the growing demand for efficient diagnosis and treatments, which is further boosting the market growth. For instance, in January 2018, Advanced Accelerator Applications launched its first-ever FDA approved peptide receptor nuclear medicine therapy for the treatment of gastroenteropancreatic neuroendocrine tumors, named Lutathera®. Similarly, Norgine B.V launched the next generation nuclear medicine, named Lymphoseek, which is designed for targeted therapy in various oncological treatments, such as breast cancer, squamous cell carcinoma, and head and neck carcinomas.

Obtain Brochure For Latest Technology Advancements @ 
https://straitsresearch.com/report/nuclear-medicine-market/request-sample

The Major Prominent Players Covered in this Report:
Curium Pharma, Nordion, Inc., Eckert & Ziegler Group, GE Healthcare, Bracco Imaging S.p.A, Bayer AG, Eczacıbaşı-Monrol Nuclear Products, Mallinckrodt plc, North Star Medical Radioisotopes, Sinotau Pharmaceuticals, SHINE Medical Technologies, and Global Medical Solutions, Ltd. & More.

By Type, Diagnostic Nuclear Medicine, SPECT Radiopharmaceuticals, Technetium-99m, Thallium-201, Gallium-67, Iodine-123, Other SPECT Isotopes, PET Radiopharmaceuticals, F-18, Ru-82, Other PET Isotopes, Therapeutic Nuclear Medicine, Alpha Emitters, Ra-223, Beta Emitters, Iodine-131, Yttrium-90, Samarium-153, Lutetium-177, Rhenium-186, Other Beta Emitters, Brachytherapy Isotopes, Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other Brachytherapy Isotopes,
By Application, Diagnostic Applications, SPECT Applications, Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications, PET Applications, Oncology, Cardiology, Neurology, Other PET Applications, Therapeutic Applications, Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Indications,
By End-User, Hospitals, Imaging Centers, Academic and Research Centers, Others ,

Growing Domestic Demand and Expanding Pharmaceutical Sector to Drive the Demand for Nuclear Medicine in the APAC Region
Asia-Pacific region is anticipated to hold the largest market share in the global Nuclear Medicine market during the forecast period 2019-2029. The growth in this region can be attributed to the presence of emerging economies like India, China, Japan, Vietnam, and Indonesia, which account for the largest share in this region. India is one of the largest producers of Nuclear Medicine and a major exporter of the product to various countries across the globe. India accounts for around 80% of the world’s exports of Nuclear Medicine. The favorable climatic conditions and growth of agricultural inputs and allied services like cold storage and warehousing in India are prompting higher production.

View this report with a detailed description and TOC @ 
https://straitsresearch.com/report/nuclear-medicine-market/toc

Recent Developments -
On 5th February 2019: Curium pharma and NRG Ltd signed an agreement for the production of Molybdenum-99, a parent radionuclide for TC 99m used in many nuclear medicines applications

On 2nd December 2019: Curium pharma acquired MAP Medical technology to expand its reach across Europe and to market its products in Nordic and Baltic countries

On 13th June 2019: Eczacýbaþý-Monrol collaborated with Telix Pharmaceuticals Limited to manufacture and distribute Nuclear medicines in Turkey and the Middle East and Africa.

Key Questions Answered in The Report:
What will the Nuclear Medicine market growth rate?
What are the key factors driving the global Nuclear Medicine market?
Who are the key manufacturers in the Nuclear Medicine market space?
What are the market opportunities, market risk, and market overview of the Nuclear Medicine market?
What are sales, revenue, and price analysis of top manufacturers of the Nuclear Medicine market?
Who are the distributors, traders, and dealers of the Nuclear Medicine market?
What are the market opportunities and threats faced by the vendors in the global Steerable Medical Devices Industry?
What are sales, revenue, and price analysis by types and applications of the Nuclear Medicine Industry?
What are sales, revenue, and price analysis by regions of Nuclear Medicine industry?
What are the driving factors contributing to market growth during the short, medium, and long term?

Key Nuclear Medicine Market Trends:
- The report identifies, determines, and forecasts the Global Nuclear Medicine Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
- Industry to Industry Holds Largest Share in the Nuclear Medicine Market
- It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
- Demand from Regional / geographical is Expected to Drive the Growth
- Rising Adoption of Market Segments in this Growth
- North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
- It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Nuclear Medicine Market.

Browse Full Report @ https://straitsresearch.com/report/nuclear-medicine-market/

Even if your business is a multinational venture or a single storefront, we believe innovation is the key to progress, in both what you build and how you promote your products and brands.

Buy Full Report with Detail Analysis with COVID-19 Impact – https://straitsresearch.com/buy-now/nuclear-medicine-market/global/

So let's put our minds together. We'll make your vision a reality and help you grow.

For more details, please contact us -
Straits Research
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY 10022
Tel: +1 646 480 7505, +44 208 068 9665
Website: https://straitsresearch.com/

About Us:
Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches. This approach of using various research and analysis strategies enables us to determine greater insights by eliminating the research costs.

This release was published on openPR.